Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers
First Claim
1. A method of eliciting an immune response in a patient who has lung cancer overexpressing an MMP1 polypeptide comprising the amino acid sequence of SEQ ID NO:
- 34, comprising administering to said patient a population of activated T cells that kill cancer cells,wherein the activated T cells are cytotoxic CD8+ T cells produced by contacting T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO;
34 in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Citations
17 Claims
-
1. A method of eliciting an immune response in a patient who has lung cancer overexpressing an MMP1 polypeptide comprising the amino acid sequence of SEQ ID NO:
- 34, comprising administering to said patient a population of activated T cells that kill cancer cells,
wherein the activated T cells are cytotoxic CD8+ T cells produced by contacting T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO;
34 in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
- 34, comprising administering to said patient a population of activated T cells that kill cancer cells,
Specification